Oncology Learning Network

This podcast features Dr David Klimstra discussing how pathologists can prepare for biomarker-directed care in extrapulmonary neuroendocrine carcinoma (epNEC). Key topics include accurate NEC classification before delta-like ligand 3 (DLL3) assessment, tissue stewardship, timing and location of immunohistochemistry testing, evolving scoring thresholds, and the importance of close pathology-oncology communication to support treatment decisions and emerging DLL3-directed strategies.

Luc Thomas, MD, PhD, discusses findings from a real-world study comparing artificial intelligence models with clinicians for skin cancer diagnosis, highlighting the strengths and limitations of artificial intelligence and reinforcing the continued importance of physician expertise in dermoscopy and melanoma detection.

In this expert commentary, Toby Maher, MD, PhD, discusses the evolving treatment landscape in progressive pulmonary fibrosis (PPF) and the potential implications of the longer-term FIBRONEER-ILD trial findings. He explores how nerandomilast may address key unmet needs in PPF, with a focus on disease progression, clinically meaningful outcomes, treatment sequencing, and the broader impact on patients, providers, and health care systems.

Dr Jamie Chaft discusses how longitudinal biomarker assessment can support treatment planning, resistance evaluation, and rebiopsy decision-making in NSCLC. Key topics include disease progression, tissue limitations, prior assay results, multidisciplinary collaboration, and individualized testing strategies. 

Dr Jamie Chaft reviews the biological and clinical differences among MET biomarkers in NSCLC, emphasizing the importance of matching the specific biomarker question to the appropriate assay. The discussion covers NGS, IHC, and FISH, as well as specimen availability, prior therapy exposure, and the evolving clinical context. 

Dr Jamie Chaft reviews the importance of early tissue stewardship in NSCLC, including how biopsy planning, tissue adequacy, and coordination across the care team can influence biomarker testing and treatment planning. The discussion emphasizes practical strategies to support current and future molecular testing needs. 

Umberto Vitolo, MD, discusses results from the phase 3 FrontMIND trial showing that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in patients with newly diagnosed high-risk diffuse large B-cell lymphoma, supporting this regimen as a potential new frontline standard of care regardless of molecular subtype.

Samantha Shenoy, NP, and Caitlin Costello, MD, discuss how risk stratification, early relapse patterns, and changes in disease trajectory can help oncology care teams recognize when a patient with multiple myeloma may warrant consideration for cellular therapy, including CAR T-cell therapy. The episode highlights the role of nurses and advanced practice providers in identifying clinical shifts and supporting timely multidisciplinary discussion.

Samantha Shenoy, NP, and Caitlin Costello, MD, discuss how oncology care teams can close the gap between recognizing a patient with multiple myeloma as a potential CAR T-cell therapy candidate and getting that patient to evaluation. The episode highlights referral readiness, documentation, shared-care coordination, and common barriers that can delay timely evaluation.

Elias Jabbour, MD, MD Anderson Cancer Center, Houston, Texas, discusses results from a phase 1 study showing that olverembatinib plus blinatumomab induced high response rates and deep MRD-negative remissions in heavily pretreated patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

This podcast examines the clinical utility of ctDNA-based MRD testing in diffuse large B-cell lymphoma, focusing on its role in post-treatment risk stratification, relapse detection, and treatment decision-making. Dr. David Russler-Germain reviews evidence showing that ctDNA MRD testing provides stronger prognostic value and earlier detection of recurrence than PET-CT imaging, supporting its growing integration into routine lymphoma care and NCCN-guided management.

This podcast explores the principles and clinical applications of circulating ctDNA-based MRD testing in diffuse large B-cell lymphoma, including how personalized sequencing assays can detect microscopic residual disease with greater sensitivity than imaging. Dr. David Russler-Germain discusses the growing evidence supporting ctDNA MRD testing for prognostication and treatment monitoring, while also addressing current limitations, such as variability across lymphoma subtypes and factors that can affect assay performance and interpretation.

This podcast reviews current and emerging approaches to residual disease detection in diffuse large B-cell lymphoma, emphasizing the role of PET-CT imaging in assessing treatment response and predicting relapse risk. Dr. David Russler-Germain discusses the limitations of PET-CT and highlights growing evidence that ctDNA-based MRD testing may provide more accurate prognostic information and improve post-treatment disease monitoring.

Guest host Cassie Kline, MD, MAS, presents a three-year update from the phase 2 FIREFLY-1 trial evaluating tovorafenib, a weekly oral type II RAF inhibitor, in recurrent or refractory pediatric low-grade glioma. She emphasizes the importance of incorporating clinically meaningful endpoints into future trials, as they may better reflect real-world patient benefit than radiographic criteria alone. Dr Kline is a pediatric neuro-oncologist at the Children's Hospital of Philadelphia and is the director of clinical research for the pediatric neuro-oncology group. 

Three cholangioscopy experts join Elena Violari, MD, RPVI for this episode of the SIO Corner.

Three cholangioscopy experts join Elena Violari, MD, RPVI for this episode of the SIO Corner.

Applications of AR in Interventional Oncology by HMP Global

Dania Daye, MD, PhD, joins the SIO Corner podcast to discuss the ways AI may be applied in interventional oncology.

Petros Grivas, MD, PhD, discusses the combination of sacituzumab govetican and pembrolizumab for metastatic urothelial carcinoma in the second-line setting.

On this episode of Blood Bytes, a hematology podcast produced by Oncology Learning Network, Steven Treon, MD, PhD, Director of the Bing Center for Waldenström’s macroglobulinemia at the Dana-Farber Cancer Institute, and Professor of Medicine at Harvard Medical School, Boston, sits down with Christian Buske, MD, Medical Director at the Comprehensive Cancer Center and the Institute of Experimental Cancer Research at the University Ulm, Germany, to discuss recent data surrounding the use of rituximab maintenance for patients with Waldenström macroglobulinemia.

Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.

Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.

Petros Grivas, MD, shares his treatment plan for a patient with metastatic urothelial cancer who has progressed following platinum-based chemotherapy.

Margherita Rimini, MD, discusses the potential link between BRCAness phenotype and response to platinum-based chemotherapy in cholangiocarcinoma.

Ruth He, MD, discusses findings from a subgroup analysis assessing outcomes by primary tumor location in biliary tract cancer treated with durvalumab.

Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.

Robert Jones, MD, University of Glasgow, UK, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following chemotherapy for patients with metastatic urothelial carcinoma who were negative for DNA repair biomarkers

Petros Grivas, MD, from the University of Washington Fred Hutchinson Cancer Research Center, shares results from the TROPHY-U-01 phase 2 trial evaluating the use of sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.

Part 2: Overcoming PARP Inhibitor and Platinum Resistance in Patients With Ovarian Cancer by HMP Global

Stay tuned for Part 2!

Guenther Koehne, MD, PhD, interviews Richard Stone, MD; Robert Soiffer, MD; and Siddhartha Mukherjee, MD, on recent therapeutic advances for hematologic malignancies with a focus on considerations for treatment selection in high-risk AML.

Shenmiao Yang, MD, highlights a multicenter, phase 3 trial comparing ibrutinib versus rituximab for advanced CLL/SLL, in which ibrutinib outperformed rituximab in all therapy outcomes.

Evolving Roles of KRAS Inhibitors in CRC by HMP Global

The Role of Tumor Mutation Burden Featuring Dr Morris by HMP Global

Dr Morris Discusses Emerging Targeted Therapies in mCRC by HMP Global

Christopher Lieu, MD, University of Colorado, shares insights to how ctDNA can detect MRD and determine genomic characterization of tumors in CRC.

Carla Casulo, MD, Associate Professor, Wilmot Cancer Institute, University of Rochester, New York, overviews the various treatments that have been approved for the management of patients with newly diagnosed and relapsed follicular lymphoma (FL).

Connie Batlevi, MD, PhD shares updated safety and efficacy data from the SYMPHONY-1 trial of tazemetostat, a first-class, oral, selective EZH2 inhibitor, for patients with FL.

Dr Loprinzi Reviews Hot Flash Treatment Strategies in BC, Part II by HMP Global

Dr Loprinzi Reviews Hot Flash Treatment Strategies for Patients With Breast Cancer by HMP Global

Dr Jacob Reviews SunRISe-1 Trial Progress in HR-NMIBC by HMP Global

Kim Chi, MD, Vancouver Prostate Centre, Discusses Phase 3 MAGNITUDE study of niraparib as well as the SPARTAN and TITAN studies, presented at 2022 ASCO GU Meeting.

Dr Melani discusses results and safety outcomes of the ViPOR trial with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide to treat R/R and untreated MCL, presented at the 2021 Annual ASH Meeting.